(Q34153343)

31 July 2017

1 reference

title

Risk assessment for recurrent venous thrombosis. (English)

1 reference

31 July 2017

0 references

2

Frits R Rosendaal

1 reference

31 July 2017

Paul Alexander Kyrle

1

1 reference

31 July 2017

Sabine Eichinger

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

3 December 2010

1 reference

31 July 2017

1 reference

31 July 2017

volume

376

1 reference

31 July 2017

issue

9757

1 reference

31 July 2017

page(s)

2032-2039

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

31 July 2017

1 reference

7 January 2021

Incidence and mortality of venous thrombosis: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

1 reference

7 January 2021

A prediction rule to identify low-risk patients with pulmonary embolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Age at first venous thromboembolism and risk of recurrence: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Risk of major hemorrhage for outpatients treated with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Symptomatic pulmonary embolism and the risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk of recurrent venous thromboembolism in patients with unprovoked symptomatic deep vein thrombosis and asymptomatic pulmonary embolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk of recurrent venous thromboembolism in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Thrombophilia, clinical factors, and recurrent venous thrombotic events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Overweight, obesity, and the risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Warfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Extended oral anticoagulant therapy after a first episode of pulmonary embolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Long-term outcomes of deep-vein thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Length of hospital stay for treatment of deep venous thrombosis and the incidence of recurrent thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Family history for venous thromboembolism and the risk for recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High-density lipoprotein and the risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The management of thrombosis in the antiphospholipid-antibody syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High plasma levels of factor VIII and the risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High plasma levels of factor VIII and risk of recurrence of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk of recurrent venous thromboembolism among patients with high factor IX levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

D-dimer levels and risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

D-dimer testing to determine the duration of anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Recurrence rate after a first venous thrombosis in patients with familial thrombophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Genetic variation in heme oxygenase 1 (HMOX1) and the risk of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

The Risk of Recurrent Venous Thromboembolism in Patients with an Arg506→Gln Mutation in the Gene for Factor V (Factor V Leiden)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Genetic susceptibility to venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Antithrombotic therapy for venous thromboembolic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Thrombophilia testing for prevention of recurrent venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Clinical guidelines for testing for heritable thrombophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

Prediction of recurrent venous thromboembolism by the activated partial thromboplastin time

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

New diagnostic strategies for pulmonary embolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960962-2

7 January 2021

10.1016/S0140-6736(10)60962-2

Identifiers

DOI

1 reference

31 July 2017

1 reference